Jun 4, 2026
CSRxP: U.S. SUPREME COURT DECISION HELPS SAFEGUARDS CRITICAL PATHWAY FOR GENERIC COMPETITION
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. Ruling Will Help Protect…
© 2026 CSRXP- All Rights Reserved
HOLDING BIG PHARMA ACCOUNTABLE
HOLDING
BIG PHARMA ACCOUNTABLE
CSRxP advocates for bipartisan solutions that hold pharmaceutical companies accountable for egregious pricing and anti-competitive practices that are the root cause of out-of-control drug prices in America.
We believe in market-based reforms to lower drug prices for patients through increased transparency, competition and value.
Big Pharma thinks it’s a master of disguise… But it can’t disguise the truth.
The BIG PHARMA Playbook
Big Pharma’s business-as-usual playbook relies on egregious pricing practices and rhetoric designed to set and keep drug prices high.
Out-of-Control Price Hikes & Launch Prices
Innovation Rhetoric Disconnected from the Facts
Blame Game Designed to Keep Prices High
Anti-Competitive Tactics & Patent Abuse
CSRxP’s Solutions
Drug prices in the United States are out of control as a direct result of the egregious pricing and anti-competitive practices of brand name pharmaceutical companies. Rising prescription drug prices threaten the affordability of our health care system, the long-term health of our nation and the vitality of our entire economy. Public opinion research finds as many as one-in-three Americans experience financial difficulty, either as a patient themselves or through a family member, affording prescription drugs. CSRxP has developed market-based solutions to restore a functioning market and lower prices for patients by increasing list price transparency, promoting competition and actual innovation and focusing on better value for patients, not better value for pharmaceutical companies.
News & Updates
Jun 3, 2026
CSRxP ENCOURAGES HOUSE JUDICIARY IP SUBCOMMITTEE TO ADVANCE BIPARTISAN, MARKET-BASED SOLUTIONS TO LOWER DRUG PRICES BY FOSTERING COMPETITION
Lawmakers Should Advance the ETHIC Act and Skinny Labels, Big Savings Act to Address Big…
Jun 2, 2026
THEY SAID IT! BROAD BASED SUPPORT FOR BIPARTISAN ETHIC ACT AND SKINNY LABELS, BIG SAVINGS ACT
Health Care Leaders and Policy Experts Agree Bipartisan, Market-Based Solutions Would…
Jun 2, 2026
DOSE OF REALITY: AARP REPORT FINDS PRICES FOR TOP-SELLING BRAND NAME DRUGS RISE DRAMATICALLY IN THE U.S. WHILE FALLING IN OTHER COUNTRIES
Report Finds List Prices for Best-Selling Medicare Part D Prescription Drugs Continue to…
Featured Content
Jun 1, 2026
Infographic: ETHIC & Skinny Labels
Two bipartisan solutions — the ETHIC Act and Skinny Labels… Read More
May 29, 2026
CSRxP: Innovation
For far too long, Big Pharma has used the false excuse that research and… Read More
Feb 10, 2026
CSRxP: Statement for the Record
Committee Chairman Guthrie, Committee Ranking Member Pallone, Subcommittee… Read More
Jan 20, 2026
CSRxP: Affordability
Big Pharma’s egregious pricing and anti-competitive practices are… Read More
Resources
Videos
Watch and learn about Big Pharma’s price-gouging techniques that are the cause of out-of-control drug prices.
Fact Sheets
Get the facts on Big Pharma’s anti-competitive tactics, like price-gouging and patent abuse that keeps drug prices high.
Infographics
Learn about how Big Pharma is driving the Rx drug pricing crisis with our infographics.
Polling
See recent surveys on American voters’ opinions on Big Pharma’s blame game and out-of-control drug pricing.
JOIN THE FIGHT
Join us in telling lawmakers: It’s time to hold Big Pharma accountable and lower Rx drug prices.